問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Principal Investigator

楊志新

List

224Cases

2020-09-01 - 2028-12-31

Phase III

Active
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    JNJ-61186372 (Amivantamab) / JNJ-73841937 (Lazertinib)

Participate Sites
8Sites

Not yet recruiting7Sites

Recruiting1Sites

2020-11-01 - 2026-06-30

Phase III

Active
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    JNJ-61186372(Amivantamab)

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2018-12-30 - 2024-12-31

Phase I

Completed
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer

  • Condition/Disease

    Advanced Non-Small Cell Lung Cancer

  • Test Drug

    JNJ-61186372、Lazertinib (JNJ-73841937)

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

夏德椿
China Medical University Hospital-Taipei

未分科

羅永鴻
Taipei Veterans General Hospital

Division of Thoracic Medicine

2020-09-01 - 2027-05-01

Phase I

Active
An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    JNJ-61186372JNJ-73841937(lazertinib)

Participate Sites
5Sites

Recruiting5Sites

2022-08-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2018-06-01 - 2027-12-31

Phase III

Active
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy (LAURA).

  • Condition/Disease

    Non Small Cell Lung Cancer

  • Test Drug

    TAGRISSO

Participate Sites
9Sites

Recruiting9Sites

2019-06-10 - 2026-09-30

Phase III

Active
A phase III, open-label, randomized study of osimertinib with or without platinum plus pemetrexed chemotherapy, as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non-small cell lung cancer (FLAURA2)

  • Condition/Disease

    A phase III, open-label, randomized study of osimertinib with or without platinum plus pemetrexed chemotherapy, as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non-small cell lung cancer (FLAURA2)

  • Test Drug

    Osimertinib (AZD9291/TAGRISSO®)

Participate Sites
13Sites

Recruiting9Sites

Terminated4Sites

2019-04-01 - 2025-12-31

Phase II

Active
A Phase II, Single Arm Study Assessing Efficacy of Osimertinib With Savolitinib in Patients With EGFRm+ MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Osimertinib Treatment (SAVANNAH Study)

  • Condition/Disease

    Locally Advanced or Metastatic Non Small Cell Lung Cancer

  • Test Drug

    TAGRISSO and Savolitinib

Participate Sites
10Sites

Recruiting10Sites

2018-12-01 - 2024-12-31

Phase III

Active
A Phase III, Randomised,Double-Blind,Placebo-Controlled,Study of Durvalumab as Consolidation Therapy in Patients With Locally Advanced,Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    Durvalumab (MEDI4736)

Participate Sites
7Sites

Recruiting3Sites

Terminated4Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2020-11-01 - 2027-06-30

Phase I

Active
A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03)

  • Condition/Disease

    Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    ENHERTUR

Participate Sites
8Sites

Recruiting8Sites

1 2 3 4 5 23
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB